OpenURL Connection Search

Select item for more details and to access through your institution.

The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α.
Published in:
Oncogene, 2008, v. 27, n. 11, p. 1501, doi. 10.1038/sj.onc.1210795
By:
- Gort, E. H.;
- van Haaften, G.;
- Verlaan, I.;
- Groot, A. J.;
- Plasterk, R. H. A.;
- Shvarts, A.;
- Suijkerbuijk, K. P. M.;
- van Laar, T.;
- van der Wall, E.;
- Raman, V.;
- van Diest, P. J.;
- Tijsterman, M.;
- Vooijs, M.
Publication type:
Article
Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study.
Published in:
PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0127895
By:
- de Groot, J. S.;
- Moelans, C. B.;
- Elias, S. G.;
- Hennink, A.;
- Verolme, B.;
- Suijkerbuijk, K. P. M.;
- Jager, A.;
- Seynaeve, C.;
- Bos, P.;
- Witkamp, A. J.;
- Ausems, M. G. E. M.;
- van Diest, P. J.;
- van der Wall, E.
Publication type:
Article
Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
Published in:
Cancer Immunology, Immunotherapy, 2021, v. 70, n. 5, p. 1491, doi. 10.1007/s00262-020-02716-3
By:
- Schuiveling, M.;
- Tonk, E. H. J.;
- Verheijden, R. J.;
- Suijkerbuijk, K. P. M.
Publication type:
Article
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Published in:
2021
By:
- Mulder, E. E. A. P.;
- de Joode, K.;
- Litière, S.;
- ten Tije, A. J.;
- Suijkerbuijk, K. P. M.;
- Boers-Sonderen, M. J.;
- Hospers, G. A. P.;
- de Groot, J. W. B.;
- van den Eertwegh, A. J. M.;
- Aarts, M. J. B.;
- Piersma, D.;
- van Rijn, R. S.;
- Kapiteijn, E.;
- Vreugdenhil, G.;
- van den Berkmortel, F. W. P. J.;
- Hoop, E. Oomen-de;
- Franken, M. G.;
- Ryll, B.;
- Rutkowski, P.;
- Sleijfer, S.
Publication type:
journal article
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
Published in:
Acta Oncologica, 2021, v. 60, n. 1, p. 69, doi. 10.1080/0284186X.2020.1818823
By:
- Boekhout, A. H.;
- Rogiers, A.;
- Jozwiak, K.;
- Boers-Sonderen, M. J.;
- van den Eertwegh, A. J.;
- Hospers, G. A.;
- de Groot, J. W. B.;
- Aarts, M. J. B.;
- Kapiteijn, E.;
- ten Tije, A. J.;
- Piersma, D.;
- Vreugdenhil, G.;
- van der Veldt, A. A.;
- Suijkerbuijk, K. P. M.;
- Rozeman, E. A.;
- Neyns, B.;
- Janssen, K. J.;
- van de Poll-Franse, L. V.;
- Blank, C. U.
Publication type:
Article
Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Published in:
Quality of Life Research, 2023, v. 32, n. 9, p. 2517, doi. 10.1007/s11136-023-03427-9
By:
- Egeler, M. D.;
- van de Poll-Franse, L. V.;
- Tissier, R.;
- Rogiers, A.;
- Boers-Sonderen, M. J.;
- van den Eertwegh, A. J.;
- Hospers, G. A.;
- de Groot, J. W. B.;
- Aarts, M. J. B.;
- Kapiteijn, E.;
- Piersma, D.;
- Vreugdenhil, G.;
- van der Veldt, A. A.;
- Suijkerbuijk, K. P. M.;
- Neyns, B.;
- Janssen, K. J.;
- Blank, C. U.;
- Retèl, V. P.;
- Boekhout, A. H.
Publication type:
Article
Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.
Published in:
Pigment Cell & Melanoma Research, 2024, v. 37, n. 1, p. 15, doi. 10.1111/pcmr.13117
By:
- Borgers, J. S. W.;
- Burgers, F. H.;
- Schina, A.;
- Van Not, O. J.;
- van den Eertwegh, A. J. M.;
- Blank, C. U.;
- Aarts, M. J. B.;
- van den Berkmortel, F. W. P. J.;
- de Groot, J. W. B.;
- Hospers, G. A. P.;
- Kapiteijn, E.;
- Piersma, D.;
- van Rijn, R. S.;
- Boer, A. M. Stevense‐den;
- van der Veldt, A. A. M.;
- Vreugdenhil, G.;
- Boers‐Sonderen, M. J.;
- Wouters, M. W. J. M.;
- Suijkerbuijk, K. P. M.;
- van Thienen, J. V.
Publication type:
Article

Found: 7

The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α.

Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study.

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.